HB0017

Monoclonal antibody

Filedunder review

Evidence outlook · regulatory review

Psoriasis: application under NMPA review

NMPA accepted the marketing application for HB0017 (anti-IL-17A) in psoriasis (2026-06). A filing is the sponsor's claim that its evidence supports approval; this platform grades the trials, not the filing. The event is listed under Regulatory events.

NCT06477237: This is a randomized, quadruple-blind, placebo-controlled Phase 3 trial using validated psoriasis response measures as its primary endpoints, but no results are yet posted to the registry, so the outcome is unknown.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Psoriasis
Phase 2 (2)
Psoriasis
NCT06592274 · Huabo Biopharm Co., Ltd.
2024-09-30 – 2026-04-10 · Psoriasis (PsO)
What this study did
Phase 1 (3)
Psoriasis
NCT05442788 · Huabo Biopharm Co., Ltd.
2021-09-02 – 2022-05-31 · Plaque Psoriasis
What this study did
Other / comorbidity
NCT04505033 · Huabo Biopharm Co., Ltd.
2020-10-02 – 2021-02-01 · Healthy Subjects
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Psoriasis: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
HB0017: this drugPhase 3Monoclonal antibodyIL-17APartial signal
NCT05531682: Co-primaries PASI 90 and sPGA 0/1 at week 12: HB0017 300 mg (n=41) vs placebo (n=40), PASI 90 69.4% vs 1.0% and sPGA 0/1 78.2% vs 1.1%, both P<0.001. The registry lists three HB0017 dosing regimens and 160 participants; the abstract reports one regimen in 81 patients and gives no result for the other two regimens.
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00195676: PGA 0/1 at 16 weeks after adalimumab retreatment: 89% in patients without relapse vs 69% in patients who relapsed; median time to relapse 141 days (178/285 stable-control patients relapsed)
NCT00237887: REVEAL: PASI 75 response rates of 71% after 16 weeks and 70% after 24 weeks of treatment with adalimumab 40 mg every other week.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaWeak signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Apremilast (Otezla)ApprovedSmall moleculePDE4Reliable signal
NCT03701763: Percentage of Participants With a Static Physician Global Assessment (sPGA) Response at Week 16 (Baseline to Week 16): Apremilast 33.1% vs Placebo 11.5%
NCT03777436: Percentage of Participants With a Modified sPGA-G Response at Week 16 (Baseline and Week 16 of the Placebo-controlled Phase): Placebo-controlled Phase: Apremilast 30 mg 39.6% (95% CI 31.2 to 48) vs Placebo-controlled Phase: Placebo 19.5% (95% CI 12.7 to 26.3)
Betamethasone Dipropionate Emollient Spray (Sernivo)ApprovedSmall moleculeGlucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Bimekizumab (Bimzelx)ApprovedMonoclonal antibodyIL-17A/FReliable signal
NCT03412747: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W + Bimekizumab 320 mg Q4W/Q8W (RS) 86.2% vs Adalimumab (RS) 47.2%
NCT03370133: Percentage of Participants With a Psoriasis Area and Severity Index 90 (PASI90) Response at Week 16 (Week 16): Bimekizumab 320 mg Q4W (RS) 85% vs Placebo (RS) 4.8% vs Ustekinumab (RS) 49.7%
Brodalumab (Siliq)ApprovedMonoclonal antibodyIL-17 receptor APartial signal
NCT02982005: Coprimary endpoints at week 12: PASI 75 and sPGA success achieved by 92.5% (brodalumab 210mg Q2W) vs 0% (placebo), significantly higher
Calcipotriene / Betamethasone Dipropionate Cream (Wynzora)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptorPartial signal
NCT03802344: Percentage Change in mPASI (Modified Psoriasis Area and Severity Index) Score (8 Weeks): MC2-01 Cream -67.5% (Standard Error 20.8) vs Cal/BDP Combination -63.5% (Standard Error 22.2) vs Vehicle -11.7% (Standard Error 21.9)
NCT03308799: PGA treatment success at week 8: 37.4% with CAL/BDP cream (MC2-01) vs 22.8% with CAL/BDP topical suspension (P<0.0001) and 3.7% with vehicle (P<0.0001) (Stein Gold et al., J Drugs Dermatol 2021).
Calcipotriene / Betamethasone Dipropionate Foam (Enstilar)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Calcipotriol / Betamethasone Dipropionate Gel (Taclonex)ApprovedSmall moleculeVitamin D receptor + Glucocorticoid receptornot yet gradedNo reviewed efficacy summary in this indication
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaReliable signal
NCT02326298: PASI 75 at Week 16 (CIMPASI-1): certolizumab pegol 200mg Q2W 66.5%, 400mg Q2W 75.8%, placebo 6.5% (P<0.0001 for both doses vs placebo).
NCT02326272: PASI 75 at Week 16 (CIMPASI-2): certolizumab pegol 200mg Q2W 81.4%, 400mg Q2W 82.6%, placebo 11.6% (P<0.0001 for both doses vs placebo).
Desoximetasone (Topicort Spray)ApprovedSmall moleculeGlucocorticoid receptor agonistPartial signal
NCT02618759: Number of Patients in Each Treatment That Have Clinical Success Based on IGA at Day 28 ± 2 (28 Days): DSXS1505 10/60 (16.7%) vs Placebo 3/59 (5.1%) missed phase 3 result · pivotal pending
NCT02932462: Clinical Success in Patients With Moderate and Severe Scalp Psoriasis (from baseline to study day 29): DSXS 1535 41/106 (38.7%) vs Placebo 43/126 (34.1%) missed phase 3 result · pivotal pending
Deucravacitinib (Sotyktu)ApprovedSmall moleculeTYK2Reliable signal
NCT04167462: The Percentage of Participants With sPGA Response of 0 or 1 (At week 16): Arm 1: BMS-986165 55.6% (95% CI 47.4 to 63.7) vs Arm 2: Placebo 6.8% (95% CI 1 to 12.5)
NCT03611751: The Number of Participants With a Static Physician's Global Assessment (sPGA) Score of 0 or 1 in Participants Receiving BMS-986165 Compared to Placebo at Week 16 (sPGA 0/1) (Week 16): BMS-986165 253/511 (49.5%) vs Placebo 22/255 (8.6%)
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Weak signal
NCT00111436: Primary endpoint (incidence of adverse events/lab changes) in this 912-patient open-label long-term safety extension (Leonardi et al. 2010, cited by this PMC review), exactly matching this NCT's registered enrollment (912) and design (open-label extension, safety of 50mg QW/BIW etanercept, 48-72 weeks): well tolerated, no significant AE/infection-rate difference between dose groups, no TB/opportunistic infection/demyelination/lymphoma cases.
Guselkumab (Tremfya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02203032: Primary endpoint (NAVIGATE trial), mean number of visits Week 28-40 with IGA 0/1 and >=2-grade improvement: guselkumab 1.5 (SD 1.57, n=135) vs continued ustekinumab 0.7 (SD 1.26, n=133); row mean score test P<0.001.
NCT02207244: Week 16 co-primary endpoints (VOYAGE 2, NCT02207244): IGA 0/1 84.1% guselkumab vs 8.5% placebo (p<0.001); PASI 90 70.0% guselkumab vs 2.4% placebo (p<0.001)
Halobetasol Propionate Foam (Lexette)
ApprovedUS marketing discontinued
Small moleculeGlucocorticoid receptorReliable signal
NCT02742441: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 30.7% vs Vehicle Foam 7.4%
NCT02368210: Percentage of Subjects Rated a "Treatment Success" Based on the Investigator's Global Assessment (IGA) (Day 15): 122-0551 Foam 25.3% vs Vehicle Foam 3.9%
Halobetasol Propionate Lotion (Bryhali)ApprovedSmall moleculeGlucocorticoid receptorPartial signal
NCT02514577: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 36.5% vs IDP-122 Vehicle Lotion 8.13%
NCT02515097: Percentage of Participants With Treatment Success at Week 8 (Week 8): IDP-122 Lotion 38.41% vs IDP-122 Vehicle Lotion 11.99%
Halobetasol Propionate / Tazarotene (Duobrii)ApprovedSmall moleculeGlucocorticoid receptor + retinoic acid receptorPartial signal
NCT02462122: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 2): 45.3% vs 12.5%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
NCT02462070: Treatment success at week 8 (at least a 2-grade IGA improvement to clear or almost clear), halobetasol propionate 0.01%/tazarotene 0.045% lotion vs vehicle (study 1): 35.8% vs 7.0%, P<.001 (Gold et al., JAAD 2018; CT.gov posted 35.76%/6.98% and 45.33%/12.51%).
Icotrokinra (Icotyde)ApprovedPeptideIL-23 receptorReliable signal
NCT06095115: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 64.7%
NCT06095102: Percentage of Participants Who Achieved an Investigator's Global Assessment (IGA) Score of 0 or 1 and a Greater Than or Equal to (>=) 2-Grade Improvement From Baseline at Week 16 (Week 16): JNJ-77242113 200 mg 56.7% vs Placebo 5.8%
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT01177800: PASI 75 response at week 10: 81.0% infliximab (5 mg/kg) vs 2.2% placebo (P < 0.001)
NCT00106847: Primary endpoint (PASI 75 at week 10), EXPRESS II trial -- official title fetched directly from the CT.gov API for this NCT matches word-for-word ('...Infliximab Induction Therapy Followed by Multiple Regimens of Maintenance Infliximab Therapy in Patients With Plaque-Type Psoriasis'): infliximab 3mg/kg 70%, 5mg/kg 75%, vs placebo 2% (P<0.001).
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Ixekizumab (Taltz)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01695239: ACR20 response at week 24 (SPIRIT-P1): ixekizumab Q2W 62.1%, ixekizumab Q4W 57.9%, placebo 30.2% — significantly more responders in both ixekizumab arms than placebo.
NCT01474512: Percentage of Participants With Static Physician Global Assessment (sPGA) of 0 or 1 (Efficacy of Ixekizumab in Participants With Moderate to Severe Plaque Ps Measure: sPGA) (Week 12): Ixe Q4W 76.4% | Ixe Q2W 81.8% vs Placebo 3.2%
Risankizumab (Skyrizi)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT02672852: Co-primary endpoints at Week 16 (IMMhance study): PASI 90 73% risankizumab vs 2% placebo; sPGA 0/1 84% risankizumab vs 7% placebo; both p<0.001
NCT02684370: PASI90 at Week 16 (UltIMMa-1 trial, NCT02684370): risankizumab 75.3% vs placebo 4.9% vs ustekinumab 42.0% (p<0.0001 vs both comparators)
Roflumilast (Zoryve Foam)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Roflumilast (Zoryve)ApprovedSmall moleculePDE4Partial signal
NCT04211389: Number of Participants Achieving Success on the Investigator Global Assessment (IGA) Scale (Week 8): Roflumilast Cream 0.3% 99/264 (37.5%) vs Vehicle Cream 9/131 (6.9%)
NCT04211363: Number of Participants Achieving Success in Investigator Global Assessment (IGA) Scale Assessment of Disease Severity at Week 8 (Baseline (Day 1) and Week 8): Rofumilast Cream 0.3% 108/255 (42.4%) vs Vehicle Cream 8/132 (6.1%)
Secukinumab (Cosentyx)ApprovedMonoclonal antibodyIL-17Reliable signal
NCT01358578: Efficacy of Secukinumab Compared to Placebo in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Measure: PASI 75 (Psoriasis Area and Severity Index) . (12 wks): AIN457 150mg 219/327 (67.0%) | AIN457 300mg 249/323 (77.1%) vs Placebo 16/324 (4.9%)
NCT01365455: Percentage of Participants Who Achieved >75 or Higher (Psoriasis Area and Severity Index) PASI Score at 12 Weeks (12 weeks): AIN457 150 mg 71.6% | AIN457 300 mg 81.6% vs Placebo 4.5%
Spesolimab (Spevigo)ApprovedMonoclonal antibodyIL-36 receptorReliable signal
NCT03782792: Proportion of Patients With a Generalized Pustular Psoriasis Physician Global Assessment (GPPGA) Pustulation Subscore of 0 Indicating no Visible Pustules at Week 1 (At Week 1.): Spesolimab 900 mg i.v SD 54.3% (95% CI 38.2% to 69.5%) vs Placebo 5.6% (95% CI 1% to 25.8%)
TapinarofApprovedSmall moleculeAryl hydrocarbon receptor, Aryl Hydrocarbon Receptor AgonistReliable signal
NCT03956355: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) 35.4% (Standard Error 2.75) vs Vehicle Cream 6% (Standard Error 2.08)
NCT03983980: Percent of Subjects Who Achieve a Physician Global Assessment (PGA) Score of Clear (0) or Almost Clear (1) With a Minimum 2-grade Improvement From Baseline at Week 12. Analyses Were Done Using Multiple Imputation (Baseline to Week 12): Tapinarof (DMVT-505) Cream Group 40.2% (Standard Error 2.82) vs Vehicle Cream Group 6.3% (Standard Error 1.99)
Tildrakizumab (Ilumya)ApprovedMonoclonal antibodyIL-23 p19Reliable signal
NCT01722331: Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8%
NCT01729754: Percentage of Participants Achieving a Psoriasis Area Sensitivity Index 75% (PASI-75) Response at Week 12 (Part 1) (Week 12): Tildrakizumab 200 mg 65.6% | Tildrakizumab 100 mg 61.2% vs Placebo 5.8% | Etanercept 50 mg 48.2%
Ustekinumab (Stelara)ApprovedMonoclonal antibodyIL-12 p40Reliable signal
NCT00307437: PASI 75 at Week 12 (intent-to-treat, PHOENIX 2 trial): placebo 15/410 vs ustekinumab 45 mg 273/409 vs ustekinumab 90 mg 311/411; p<0.001 for each dose vs placebo.
NCT00267969: PASI 75 at week 12: ustekinumab 45mg 67.1% vs placebo 3.1% (difference 63.9%, 95% CI 57.8-70.1, p<0.0001); ustekinumab 90mg 66.4% vs placebo 3.1% (difference 63.3%, 95% CI 57.1-69.4, p<0.0001).
Ustekinumab-Aauz (Otulfi)Approved—IL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Aekn (Selarsdi)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Auub (Wezlana)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Hmny (Starjemza)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Srlf (Imuldosa)ApprovedMonoclonal antibodyIL-12 p40Reliable signalFeatured results are non-efficacy only in this race
Ustekinumab-Stba (Steqeyma)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Ustekinumab-Ttwe (Pyzchiva)ApprovedMonoclonal antibodyIL-12 p40not yet gradedNo reviewed efficacy summary in this indication
Amdokitug (Yisaituo)Phase 3Monoclonal antibodyIL-17Anot yet gradedNo reviewed efficacy summary in this indication
Dimethyl Fumarate (Skilarence)Phase 3Small moleculeNrf2 pathway (fumaric acid ester)not yet gradedNo reviewed efficacy summary in this indication
EbdarokimabPhase 3Monoclonal antibodyIL-12/23 p40not yet gradedNo reviewed efficacy summary in this indication
EnvudeucitinibPhase 3Small moleculeTYK2Reliable signal
NCT06586112: PASI-75 at week 16 (ONWARD 1): 76.5% envudeucitinib vs 18.7% placebo; PASI-90: 59.9% vs 4.8%; PASI-100: 29.4% vs 0.9% (P<.0001 for all)
NCT06588738: ONWARD2, week 16 co-primary endpoints vs placebo (intention-to-treat, nonresponder imputation): PASI 75 70.4% with envudeucitinib 40 mg twice daily (n=433) vs 13.7% with placebo (n=211); sPGA 0/1 57.3% vs 5.7%; both P < 0.0001 (Cochran-Mantel-Haenszel). PASI 90: 53.1% vs 4.3%. Apremilast 30 mg twice daily (n=215): PASI 75 38.6%, sPGA 0/1 27.4% (Alumis AAD 2026 late-breaking presentation).
FadeucravacitinibPhase 3Small moleculeTYK2Partial signal
NCT06109818: PASI 75 at week 12: 77.3% (6 mg) and 78.6% (9 mg) vs 11.6% (placebo); primary endpoint achieved
GumokimabPhase 3Monoclonal antibodyIL-17APartial signal
NCT06066125: PASI 75 response at Week 12: 94.6% with gumokimab; PASI 100: 47.7%
HS-10374Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
HS-20137Phase 3Monoclonal antibodyIL-23 p19not yet gradedNo reviewed efficacy summary in this indication
ImsidolimabPhase 3Monoclonal antibodyIL-36 receptorPartial signalFeatured results are non-efficacy only in this race
LecankitugPhase 3Monoclonal antibodyIL-17A/Fnot yet gradedNo reviewed efficacy summary in this indication
MufemilastPhase 3Small moleculePDE4Partial signal
NCT04839328: PASI75 比例分别为 53.6% vs 16.0%,sPGA 0/1 率分别为 31.3% vs 6.4% (PASI75 at week 16: Hemay005 53.6% vs placebo 16.0%; sPGA 0/1: 31.3% vs 6.4%)
NetakimabPhase 3Monoclonal antibodyIL-17Reliable signal
NCT03390101: • The Proportion (Number) of Patients in Each Study Arm Who Achieved a PASI 75 at Week 12 of Treatment (week 12): BCD-085 Q2W 66/85 (77.6%) | BCD-085 Q4W 70/84 (83.3%) vs Placebo 0/44 (0.0%)
Nomelcitinib (D-2570)Phase 3Small moleculeTYK2Partial signal
NCT06278350: Primary endpoint PASI 75 at week 12: ≥85% in all three D-2570 dose groups vs 12.5% with placebo (p<0.001)
PicankibartPhase 3Monoclonal antibodyIL-23 p19Reliable signal
NCT06049810: PASI 90 maintenance at Week 56: 89.3% (100 mg) and 90.1% (200 mg) picankibart-maintenance groups vs 37.7% and 51.7% in the corresponding randomized-withdrawal groups; P < 0.0001 for both comparisons
NCT05645627: Co-primary 1, PASI 90 at week 16: 80.3% picankibart 200 mg vs 2.0% placebo (p<0.0001), met. Co-primary 2, sPGA 0/1 at week 16: 93.5% vs 13.1% (p<0.0001), met. Response rates from the JAAD paper; p-values from the Innovent release, as the paper abstract does not print them.
RoconkibartPhase 3Monoclonal antibodyIL-17AReliable signal
NCT05975268: Both co-primary endpoints and key secondary endpoints showed statistically significant and clinically meaningful improvements
UA026Phase 1Small moleculeIL-17Anot yet gradedNo reviewed efficacy summary in this indication
VelvakimentDiscontinuedAntibody fragmentIL-17APartial signalNo reviewed efficacy summary in this indication

Large race: only the 65 furthest-along competitors are listed; 54 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow HB0017 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1PsoriasisRecruiting
Est. primary completion 2026-12-31 · NCT07920861 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026Filing acceptedNMPA accepted the marketing application for HB0017 (anti-IL-17A) in psoriasis
CN, NMPA · Source ↗
November 2025Topline resultPhase 3 of HB0017 in plaque psoriasis met all primary and key secondary efficacy endpoints